



Federal Communications Commission
Equipment Authorization Branch
7435 Oakland Mills Road
Columbia, MD 21046

Subject: Request for Confidentiality Regarding FCC ID 2BG3YC01

Pursuant to the provisions of Sections 0.457(d) and 0.459 of the Commission's rules (47 CFR §§ 0.457, 0.459) and FCC Guidance Document KDB 726920, SetPoint Medical Corp. hereby requests confidential treatment for documents filed with the Commission in connection with the application for equipment authorization referenced above. SetPoint Medical requests that Long Term Confidentiality is applied to the following documents:

Schematic Diagram
Block Diagram
Theory of Operation

These documents reveal detailed technical and design information that is protected by SetPoint Medical as confidential and proprietary trade secrets. This information has been disclosed to those required to maintain its confidentiality, and it is not customarily disclosed to the public even after commercial release of a device. As a result, disclosure of this information by the Commission would harm SetPoint Medical by giving competitors an unfair advantage even after commercial release of the device.

In addition to the above mentioned documents, pursuant to Public Notice DA 04-1705 of the Commission's policy, in order to comply with the marketing regulations in 47 CFR §2.803 and the importation rules in 47 CFR §2.1204, while ensuring that business sensitive information remains confidential until the actual marketing of newly authorized devices, SetPoint Medical requests that Short Term Confidentiality is applied to the following documents for one hundred eighty days after the date the grant of equipment authorization is issued:

Internal Photographs
Test Setup Photographs

These documents reveal technical and design information that has not been publicly disclosed in marketing materials and is protected by SetPoint Medical as confidential and proprietary trade secrets. This information has been disclosed to those required to maintain its confidentiality, and it is not customarily disclosed publicly prior to the commercial release of the device. As a result, disclosure of this information by the Commission prior to commercial release would harm SetPoint Medical by giving competitors an unfair market advantage. SetPoint Medical believes the period of confidentiality is necessary to protect the information until the commercial release of a device.

A handwritten signature in black ink, appearing to read 'Bill Calle'.

*Electronically signed by: Bill Calle
Reason: I am the authorized approver
Date: Sep 13, 2024 13:23 PDT*

Bill Calle
VP, Product Development

2BG3YC01 Confidentiality Request Letter

Final Audit Report

2024-09-13

Created:	2024-09-13
By:	Evan Gonzales (egonzales@setpointmedical.com)
Status:	Signed
Transaction ID:	CBJCHBCAABAALUKCKjGVfyAIA48tmaMo0n0koJxMEEPy

"2BG3YC01 Confidentiality Request Letter" History

-  Document created by Evan Gonzales (egonzales@setpointmedical.com)
2024-09-13 - 8:08:20 PM GMT
-  Document emailed to Bill Calle (bcalle@setpointmedical.com) for signature
2024-09-13 - 8:08:43 PM GMT
-  Email viewed by Bill Calle (bcalle@setpointmedical.com)
2024-09-13 - 8:23:00 PM GMT
-  Bill Calle (bcalle@setpointmedical.com) authenticated with Adobe Acrobat Sign.
Challenge: The user opened the agreement.
2024-09-13 - 8:23:18 PM GMT
-  Document e-signed by Bill Calle (bcalle@setpointmedical.com)
Signing reason: I am the authorized approver
Signature Date: 2024-09-13 - 8:23:48 PM GMT - Time Source: server
-  Agreement completed.
2024-09-13 - 8:23:48 PM GMT